SCHEMBL2970975

SCHEMBL2970975

CC(=NO)c1ccc(Oc2ccc(Cl)cc2N)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
CYP1A2 P05177 2/20 0.62
CYP2C9 P11712 2/20 0.62
CYP2C19 P33261 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP2D6 P10635 1/20 0.62
HPGD P15428 1/20 0.62
CYP3A4 P08684 1/20 0.56
HTT P42858 2/20 0.51
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
USP2 O75604 1/20 0.40
FURIN P09958 1/20 0.40
PDE7A Q13946 1/20 0.39
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970972 1.00 MAPT (0.62) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2544053 0.83 SCN9A (0.44) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL753409 0.83 SCN9A (0.44) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2964396 0.82 MAPT (0.66) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL16255397 0.80 FURIN (0.50) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL7140487 0.79 MAPT (0.96) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL32674568 0.79 MAPT (0.96) MAPTCYP1A2CYP2C9CYP2C19MEN1
Hydrochloric Acid SCHEMBL11515445 0.78 MAPT (1.00) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL359771 0.77 SMN1; SMN2 (0.77) MAPTCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL11409091 0.77 MAPT (0.77) MAPTCYP1A2CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885CYP1A2 877/4885CYP2C9 738/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885CYP1A2 877/4885CYP2C9 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.